Inocras to Offer High Quality and Cost-Effective Whole Genome Sequencing and Bioinformatics Services on Ultima UG 100TM platform

SAN DIEGO

Inocras Inc., a leader in whole genome sequencing and bioinformatics, announced today that it is now offering whole genome sequencing services using the UG 100^TM sequencer from Ultima Genomics, Inc., a developer of a revolutionary new ultra-high throughput, low cost, next-generation sequencing (NGS) architecture.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240814284150/en/

Through its CAP accredited and CLIA certified facility in San Diego, Inocras has offered whole genome sequencing and bioinformatics services for academic and clinical research organizations as well as pharmaceutical and biotechnology companies. With the addition of Ultima’s UG 100, Inocras now provides more options to customers seeking comprehensive whole genome sequencing and analytics services.

The UG 100, Ultima’s first commercial product, leverages a unique sequencing architecture featuring an open silicon wafer substrate to replace the traditional flow cells as well as a new sequencing chemistry that reduces overall sequencing costs.

“Having completed exhaustive feasibility tests, we are ready to offer whole genome sequencing and bioinformatics services on Ultima’s UG 100 system.” said Jehee Suh, CEO of Inocras Inc. “This enables us to meet diverse needs of our customers in the genomics community with price flexibility. We announced collaboration with Ultima in 2023 with a shared vision to make whole genome insights affordable. That future is already here today.”

“Inocras’s whole genome sequencing and bioinformatics capabilities showcase the power of Ultima’s ultra-high throughput, low-cost sequencing technologies,” said Gilad Almogy, Founder and CEO of Ultima Genomics. “We are very excited to see our shared vision of affordable genomic solutions coming to fruition.”

About Inocras, Inc:

Inocras Inc. (formerly Genome Insight, Inc) is a pioneering provider of whole genome sequencing and analytics for cancer and rare diseases. The company is dedicated to unlocking the full potential of whole genomic data to enable precision health for everyone. For researchers, it provides customizable research solutions including whole genome sequencing, bioinformatics, and expert advisory services. For clinicians and patients, it offers CancerVision, a cancer profiling tumor-normal paired whole genome test, and RareVision, a rare disease diagnosis whole genome test. It operates a CLIA certified and CAP accredited lab in San Diego. For more information about Inocras, please visit Inocras.com.

About Ultima Genomics, Inc.

Ultima Genomics is unleashing the power of genomics at scale. The Company’s mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology’s complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima’s revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century. To learn more, visit www.ultimagenomics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240814284150/en/